Almirall takes option on Dermira’s eczema drug lebrikizumabSpain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, Share XAlmirall takes option on Dermira’s eczema drug lebrikizumabhttps://pharmaphorum.com/news/almirall-takes-option-on-dermiras-eczema-drug-lebrikizumab/
Sanofi/Regeneron asthma trial casts doubt on IL-33 class prospectsThe good news for Sanofi and Regeneron is that their interleukin-33-targeting drug seems to work in asthma. The Share XSanofi/Regeneron asthma trial casts doubt on IL-33 class prospectshttps://pharmaphorum.com/news/sanofi-regeneron-asthma-trial-casts-doubt-il-33-class-prospects/
FDA approves Regeneron’s Eylea for diabetic retinopathyRegeneron’s Eylea injection has been approved in the US for diabetic retinopathy, to treat all stages of the Share XFDA approves Regeneron’s Eylea for diabetic retinopathyhttps://pharmaphorum.com/news/fda-approves-regenerons-eylea-for-diabetic-retinopathy/
Sanofi claims EU okay for Dupixent in asthmaSanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important Share XSanofi claims EU okay for Dupixent in asthmahttps://pharmaphorum.com/news/sanofi-claims-eu-okay-for-dupixent-in-asthma/
Cholesterol drug from Sanofi/Regeneron gains US CV risk reduction useSanofi and Regeneron’s Praluent cholesterol drug has been approved in the US to help prevent cardiovascular events, a Share XCholesterol drug from Sanofi/Regeneron gains US CV risk reduction usehttps://pharmaphorum.com/news/cholesterol-drug-from-sanofi-regeneron-gains-us-cv-risk-reduction-use/
Sanofi/Regeneron skin cancer drug among flurry of decisions from EU regulatorsA new drug for advanced skin cancer and a long-lasting treatment for haemophilia A are among a group Share XSanofi/Regeneron skin cancer drug among flurry of decisions from EU regulatorshttps://pharmaphorum.com/news/sanofi-regeneron-skin-cancer-drug-among-flurry-of-approvals-from-eu-regulators/
Regeneron and Alnylam announce $1bn collaborationRegeneron has signed a collaboration deal potentially worth $1 billion with RNAi experts Alnylam Pharmaceuticals, to develop and Share XRegeneron and Alnylam announce $1bn collaborationhttps://pharmaphorum.com/news/regeneron-and-alnylam-announce-1bn-collaboration/
Praluent approved to reduce CV risk in EuropeThe European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic Share XPraluent approved to reduce CV risk in Europehttps://pharmaphorum.com/news/praluent-approved-to-reduce-cv-risk-in-europe/
Sanofi/Regeneron’s Dupixent shows more promise in nasal polypsSanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase Share XSanofi/Regeneron’s Dupixent shows more promise in nasal polypshttps://pharmaphorum.com/news/sanofi-regenerons-dupixent-shows-more-promise-in-nasal-polyps/
